[Does transurethral resection cause metastatic dissemination of hormone treated prostatic cancer?].
The evolution of non-metastatic prostate cancer treated with hormonal therapy does not appear to be affected by the performance of a transurethral resection (TUR) as a measure to expedite the common urinary tract. Of 82 patients followed for an interval ranging from 6 months to 15 years, 3 of 45 patients (6.7%) undergoing RUT experienced metastatic dissemination, while the same happened in 2 of 37 (5.4%) patients who did not undergo RUT, p being NS. The group of patients requiring RUT, however, experienced higher local progression rates, 22.2% vs 5.4%, a situation not ascribable to the RUT procedure but to the fact that such surgery was selectively indicated in neoplasias with larger tumoral mass.
Servicio de Urología, Hospital General Valle de Hebrón, Barcelona.
J
J
Morote Robles
C
C
Reig Ruiz
J
J
Vila Barja
J A
JA
Lorente Garin
M A
MA
López Pacios
J A
JA
de Torres Mateos
A
A
Soler Roselló
D000230:Adenocarcinoma / Q000209:etiology / Q000556:secondary* / Q000601:surgery / Q000628:therapy; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D011468:Prostatectomy / Q000009:adverse effects*; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000601:surgery / Q000628:therapy; D012189:Retrospective Studies
Produce la RTU diseminación metastásica en el cáncer de próstata tratado hormonalmente?